NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Forecast, Price & News $2.63 -0.02 (-0.75%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$2.60▼$2.7450-Day Range$2.63▼$4.0952-Week Range$2.08▼$5.16Volume105,879 shsAverage Volume244,376 shsMarket Capitalization$124.95 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Puma Biotechnology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside204.2% Upside$8.00 Price TargetShort InterestBearish4.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 5 Articles This WeekInsider TradingSelling Shares$272,466 Sold Last QuarterProj. Earnings Growth-29.27%From $0.41 to $0.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector785th out of 973 stocksPharmaceutical Preparations Industry375th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Puma Biotechnology has a forecasted upside of 204.2% from its current price of $2.63.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.67% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 3.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PBYI. Previous Next 1.8 News and Social Media Coverage News SentimentPuma Biotechnology has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Puma Biotechnology this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $272,466.00 in company stock.Percentage Held by Insiders22.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.97% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to decrease by -29.27% in the coming year, from $0.41 to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is -52.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is -52.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioPuma Biotechnology has a PEG Ratio of 1.07. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Puma Biotechnology (NASDAQ:PBYI) StockPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Read More PBYI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBYI Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comPuma Biotechnology, Inc. Expected to Earn Q4 2023 Earnings of $0.27 Per Share (NASDAQ:PBYI)September 22, 2023 | americanbankingnews.comPuma Biotechnology (NASDAQ:PBYI) Rating Reiterated by HC WainwrightSeptember 29, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 22, 2023 | americanbankingnews.comZacks Research Weighs in on Puma Biotechnology, Inc.'s FY2025 Earnings (NASDAQ:PBYI)September 21, 2023 | marketwatch.comPuma Biotechnology Gets Orphan Designation for Small Cell Lung Cancer DrugSeptember 21, 2023 | marketwatch.comPuma Biotechnology Stock Up 6.9% on New FDA Orphan Drug DesignationSeptember 21, 2023 | finance.yahoo.comPuma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung CancerSeptember 19, 2023 | americanbankingnews.comCritical Analysis: Hoth Therapeutics (NASDAQ:HOTH) versus Puma Biotechnology (NASDAQ:PBYI)September 29, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 31, 2023 | finance.yahoo.comPuma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 4, 2023 | finance.yahoo.comQ2 2023 Puma Biotechnology Inc Earnings CallAugust 4, 2023 | finance.yahoo.comPuma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales OutperformAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Puma Biotechnology (PBYI)August 3, 2023 | msn.comPuma Biotech (PBYI) Surpasses Q2 Earnings and Revenue EstimatesJuly 20, 2023 | finance.yahoo.comPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial ResultsJuly 7, 2023 | gurufocus.comInsider Sell: Chief Commercial Officer Jeffrey Ludwig Sells 12,103 Shares of Puma Biotechnology IncJune 4, 2023 | finance.yahoo.comPuma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual MeetingJune 1, 2023 | msn.comPBYI or TECH: Which Is the Better Value Stock Right Now?May 28, 2023 | finance.yahoo.comShould You Be Concerned About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE?May 16, 2023 | msn.comPBYI vs. TECH: Which Stock Is the Better Value Option?May 6, 2023 | msn.comHC Wainwright & Co. Reiterates Puma Biotechnology (PBYI) Buy RecommendationMay 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Regeneron (REGN) and Puma Biotechnology (PBYI)May 5, 2023 | finance.yahoo.comPuma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/YMay 5, 2023 | finance.yahoo.comQ1 2023 Puma Biotechnology Inc Earnings CallMay 4, 2023 | msn.comPuma Biotechnology: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comPuma Biotechnology Reports First Quarter Financial ResultsApril 17, 2023 | finance.yahoo.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%See More Headlines Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Company Calendar Last Earnings8/03/2023Today9/29/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PBYI CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees192Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+204.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E Ratio6.41 P/E Growth1.07Net IncomeN/A Net Margins-1.09% Pretax Margin-0.76% Return on Equity-10.00% Return on Assets-1.22% Debt Debt-to-Equity Ratio2.88 Current Ratio1.97 Quick Ratio1.84 Sales & Book Value Annual Sales$228 million Price / Sales0.55 Cash Flow$0.19 per share Price / Cash Flow13.71 Book Value$0.47 per share Price / Book5.60Miscellaneous Outstanding Shares47,510,000Free Float36,725,000Market Cap$124.95 million OptionableOptionable Beta1.06 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Alan H. Auerbach (Age 53)Founder, Chairman, Pres, CEO & Sec. Comp: $1.74MMr. Maximo F. Nougues (Age 54)CFO & Principal Accounting Officer Comp: $781.47kDr. Alvin F. Wong Pharm.d. (Age 70)Chief Scientific Officer Comp: $809.69kMr. Douglas Hunt B.Sc. (Age 58)FRAPS, Sr. VP of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law Comp: $632.65kMr. Jeffrey Jerome Ludwig (Age 57)Chief Commercial Officer Comp: $916.85kMr. Mariann OhanesianSr. Director of Investor RelationsMore ExecutivesKey CompetitorsInflaRxNASDAQ:IFRXLongboard PharmaceuticalsNASDAQ:LBPHBioVieNASDAQ:BIVIAadi BioscienceNASDAQ:AADIAnnexonNASDAQ:ANNXView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCBought 25,000 shares on 8/21/2023Ownership: 0.426%XTX Topco LtdSold 3,169 shares on 8/15/2023Ownership: 0.165%Caxton Associates LPSold 8,363 shares on 8/15/2023Ownership: 0.034%Citadel Advisors LLCBought 2,000 shares on 8/15/2023Ownership: 0.000%State Street CorpSold 22,021 shares on 8/14/2023Ownership: 0.351%View All Insider TransactionsView All Institutional Transactions PBYI Stock - Frequently Asked Questions Should I buy or sell Puma Biotechnology stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares. View PBYI analyst ratings or view top-rated stocks. What is Puma Biotechnology's stock price forecast for 2023? 1 Wall Street analysts have issued 12-month price targets for Puma Biotechnology's stock. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 204.2% from the stock's current price. View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts. How have PBYI shares performed in 2023? Puma Biotechnology's stock was trading at $4.23 on January 1st, 2023. Since then, PBYI shares have decreased by 37.8% and is now trading at $2.63. View the best growth stocks for 2023 here. When is Puma Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our PBYI earnings forecast. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The biopharmaceutical company had revenue of $54.60 million for the quarter, compared to analyst estimates of $51.37 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 10.00% and a negative net margin of 1.09%. What guidance has Puma Biotechnology issued on next quarter's earnings? Puma Biotechnology updated its third quarter 2023 earnings guidance on Friday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $54.00 million-$58.00 million, compared to the consensus revenue estimate of $60.49 million. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and What is Puma Biotechnology's stock symbol? Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI." How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Puma Biotechnology's stock price today? One share of PBYI stock can currently be purchased for approximately $2.63. How much money does Puma Biotechnology make? Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $124.95 million and generates $228 million in revenue each year. How many employees does Puma Biotechnology have? The company employs 192 workers across the globe. How can I contact Puma Biotechnology? Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501. This page (NASDAQ:PBYI) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.